APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Products

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuroprotective Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174016660322 December 2025197 pages

Choose your research edition.

Industry ResearchNeuroprotective Products Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Products Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Neuroprotective Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Products Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Products Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neuroprotective Products market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroprotective Products include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Pfizer Inc, GlaxoSmithKline plc., Biogen, AstraZeneca, Sunovion Pharmaceuticals Inc and NeuroVive Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroprotective Products market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroprotective Products and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroprotective Products sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroprotective Products market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroprotective Products Segment by Company

Teva Pharmaceutical Industries Ltd

Novartis

Merck KGaA

Pfizer Inc

GlaxoSmithKline plc.

Biogen

AstraZeneca

Sunovion Pharmaceuticals Inc

NeuroVive Pharmaceutical

Neuren Pharmaceuticals

Hikma Pharmaceuticals PLC

Genervon Biopharmaceuticals

Ceregene

Bionure

Bioniz Theraputics.

BHR Pharma

Allon therapeutics

Neuroprotective Products Segment by Type

Cholinesterase inhibitors

NMDA receptor antagonists

Others

Neuroprotective Products Segment by Application

Alzheimer's disease

Multiple sclerosis

Others

Neuroprotective Products Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroprotective Products market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuroprotective Products manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neuroprotective Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neuroprotective Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neuroprotective Products Industry Trends Table 2. Neuroprotective Products Industry Drivers Table 3. Neuroprotective Products Industry Opportunities and Challenges Table 4. Neuroprotective Products Industry Restraints Table 5. Global Neuroprotective Products Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neuroprotective Products Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neuroprotective Products Sales by Manufacturers (tons) & (2021-2026) Table 8. Global Neuroprotective Products Sales Market Share by Manufacturers Table 9. Global Neuroprotective Products Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Neuroprotective Products Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neuroprotective Products Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neuroprotective Products Manufacturers, Product Type & Application Table 13. Global Neuroprotective Products Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroprotective Products by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cholinesterase inhibitors Table 17. Major Manufacturers of NMDA receptor antagonists Table 18. Major Manufacturers of Others Table 19. Global Neuroprotective Products Sales by Type 2021 VS 2025 VS 2032 (tons) Table 20. Global Neuroprotective Products Sales by Type (2021-2026) & (tons) Table 21. Global Neuroprotective Products Sales by Type (2027-2032) & (tons) Table 22. Global Neuroprotective Products Sales Market Share by Type (2021-2026) Table 23. Global Neuroprotective Products Sales Market Share by Type (2027-2032) Table 24. Global Neuroprotective Products Revenue by Type 2021 VS 2025 VS 2032 (tons) Table 25. Global Neuroprotective Products Revenue by Type (2021-2026) & (tons) Table 26. Global Neuroprotective Products Revenue by Type (2027-2032) & (tons) Table 27. Global Neuroprotective Products Revenue Market Share by Type (2021-2026) Table 28. Global Neuroprotective Products Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Alzheimer's disease Table 30. Major Manufacturers of Multiple sclerosis Table 31. Major Manufacturers of Others Table 32. Global Neuroprotective Products Sales by Application 2021 VS 2025 VS 2032 (tons) Table 33. Global Neuroprotective Products Sales by Application (2021-2026) & (tons) Table 34. Global Neuroprotective Products Sales by Application (2027-2032) & (tons) Table 35. Global Neuroprotective Products Sales Market Share by Application (2021-2026) Table 36. Global Neuroprotective Products Sales Market Share by Application (2027-2032) Table 37. Global Neuroprotective Products Revenue by Application 2021 VS 2025 VS 2032 (tons) Table 38. Global Neuroprotective Products Revenue by Application (2021-2026) & (tons) Table 39. Global Neuroprotective Products Revenue by Application (2027-2032) & (tons) Table 40. Global Neuroprotective Products Revenue Market Share by Application (2021-2026) Table 41. Global Neuroprotective Products Revenue Market Share by Application (2027-2032) Table 42. Global Neuroprotective Products Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 43. Global Neuroprotective Products Sales by Region (2021-2026) & (tons) Table 44. Global Neuroprotective Products Sales Market Share by Region (2021-2026) Table 45. Global Neuroprotective Products Sales Forecasted by Region (2027-2032) & (tons) Table 46. Global Neuroprotective Products Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 48. North America Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 49. North America Neuroprotective Products Sales by Country (2027-2032) & (tons) Table 50. Europe Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 51. Europe Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 52. Europe Neuroprotective Products Sales by Country (2027-2032) & (tons) Table 53. Asia Pacific Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 54. Asia Pacific Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 55. Asia Pacific Neuroprotective Products Sales by Country (2027-2032) & (tons) Table 56. South America, Middle East and Africa Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 57. South America, Middle East and Africa Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 58. South America, Middle East and Africa Neuroprotective Products Sales by Country (2027-2032) & (tons) Table 59. Global Neuroprotective Products Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Neuroprotective Products Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Neuroprotective Products Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Neuroprotective Products Revenue Market Share by Region (2021-2026) Table 63. Global Neuroprotective Products Revenue Market Share by Region (2027-2032) Table 64. Teva Pharmaceutical Industries Ltd Company Information Table 65. Teva Pharmaceutical Industries Ltd Business Overview Table 66. Teva Pharmaceutical Industries Ltd Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical Industries Ltd Neuroprotective Products Product Portfolio Table 68. Teva Pharmaceutical Industries Ltd Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novartis Neuroprotective Products Product Portfolio Table 73. Novartis Recent Development Table 74. Merck KGaA Company Information Table 75. Merck KGaA Business Overview Table 76. Merck KGaA Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck KGaA Neuroprotective Products Product Portfolio Table 78. Merck KGaA Recent Development Table 79. Pfizer Inc Company Information Table 80. Pfizer Inc Business Overview Table 81. Pfizer Inc Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Inc Neuroprotective Products Product Portfolio Table 83. Pfizer Inc Recent Development Table 84. GlaxoSmithKline plc. Company Information Table 85. GlaxoSmithKline plc. Business Overview Table 86. GlaxoSmithKline plc. Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline plc. Neuroprotective Products Product Portfolio Table 88. GlaxoSmithKline plc. Recent Development Table 89. Biogen Company Information Table 90. Biogen Business Overview Table 91. Biogen Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Biogen Neuroprotective Products Product Portfolio Table 93. Biogen Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. AstraZeneca Neuroprotective Products Product Portfolio Table 98. AstraZeneca Recent Development Table 99. Sunovion Pharmaceuticals Inc Company Information Table 100. Sunovion Pharmaceuticals Inc Business Overview Table 101. Sunovion Pharmaceuticals Inc Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Sunovion Pharmaceuticals Inc Neuroprotective Products Product Portfolio Table 103. Sunovion Pharmaceuticals Inc Recent Development Table 104. NeuroVive Pharmaceutical Company Information Table 105. NeuroVive Pharmaceutical Business Overview Table 106. NeuroVive Pharmaceutical Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. NeuroVive Pharmaceutical Neuroprotective Products Product Portfolio Table 108. NeuroVive Pharmaceutical Recent Development Table 109. Neuren Pharmaceuticals Company Information Table 110. Neuren Pharmaceuticals Business Overview Table 111. Neuren Pharmaceuticals Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Neuren Pharmaceuticals Neuroprotective Products Product Portfolio Table 113. Neuren Pharmaceuticals Recent Development Table 114. Hikma Pharmaceuticals PLC Company Information Table 115. Hikma Pharmaceuticals PLC Business Overview Table 116. Hikma Pharmaceuticals PLC Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Hikma Pharmaceuticals PLC Neuroprotective Products Product Portfolio Table 118. Hikma Pharmaceuticals PLC Recent Development Table 119. Genervon Biopharmaceuticals Company Information Table 120. Genervon Biopharmaceuticals Business Overview Table 121. Genervon Biopharmaceuticals Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Genervon Biopharmaceuticals Neuroprotective Products Product Portfolio Table 123. Genervon Biopharmaceuticals Recent Development Table 124. Ceregene Company Information Table 125. Ceregene Business Overview Table 126. Ceregene Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Ceregene Neuroprotective Products Product Portfolio Table 128. Ceregene Recent Development Table 129. Bionure Company Information Table 130. Bionure Business Overview Table 131. Bionure Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Bionure Neuroprotective Products Product Portfolio Table 133. Bionure Recent Development Table 134. Bioniz Theraputics. Company Information Table 135. Bioniz Theraputics. Business Overview Table 136. Bioniz Theraputics. Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Bioniz Theraputics. Neuroprotective Products Product Portfolio Table 138. Bioniz Theraputics. Recent Development Table 139. BHR Pharma Company Information Table 140. BHR Pharma Business Overview Table 141. BHR Pharma Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. BHR Pharma Neuroprotective Products Product Portfolio Table 143. BHR Pharma Recent Development Table 144. Allon therapeutics Company Information Table 145. Allon therapeutics Business Overview Table 146. Allon therapeutics Neuroprotective Products Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Allon therapeutics Neuroprotective Products Product Portfolio Table 148. Allon therapeutics Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Neuroprotective Products Distributors List Table 152. Neuroprotective Products Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Neuroprotective Products Product Image Figure 2. Global Neuroprotective Products Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Products Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroprotective Products Sales (2021-2032) & (tons) Figure 5. Global Neuroprotective Products Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Neuroprotective Products Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cholinesterase inhibitors Image Figure 9. NMDA receptor antagonists Image Figure 10. Others Image Figure 11. Global Neuroprotective Products Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 12. Global Neuroprotective Products Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Neuroprotective Products Sales Market Share by Type (2021-2032) Figure 14. Global Neuroprotective Products Revenue by Type (2021 VS 2025 VS 2032) & (tons) Figure 15. Global Neuroprotective Products Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Neuroprotective Products Revenue Market Share by Type (2021-2032) Figure 17. Alzheimer's disease Image Figure 18. Multiple sclerosis Image Figure 19. Others Image Figure 20. Global Neuroprotective Products Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 21. Global Neuroprotective Products Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Neuroprotective Products Sales Market Share by Application (2021-2032) Figure 23. Global Neuroprotective Products Revenue by Application (2021 VS 2025 VS 2032) & (tons) Figure 24. Global Neuroprotective Products Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Neuroprotective Products Revenue Market Share by Application (2021-2032) Figure 26. North America Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 27. North America Neuroprotective Products Sales Market Share by Country (2021-2032) Figure 28. U.S. Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 29. Canada Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 30. Mexico Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 31. Europe Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 32. Europe Neuroprotective Products Sales Market Share by Country (2021-2032) Figure 33. Germany Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 34. France Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 35. U.K. Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 36. Italy Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 37. Netherlands Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 38. Asia Pacific Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 39. Asia Pacific Neuroprotective Products Sales Market Share by Country (2021-2032) Figure 40. China Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 41. Japan Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 42. South Korea Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 43. Southeast Asia Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 44. India Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 45. Australia Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 46. South America, Middle East and Africa Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 47. South America, Middle East and Africa Neuroprotective Products Sales Market Share by Country (2021-2032) Figure 48. Brazil Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 49. South Africa Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 50. Saudi Arabia Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 51. Turkey Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 52. Argentina Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 53. UAE Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 54. Egypt Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 55. Chile Neuroprotective Products Sales and Growth Rate (2021-2032) & (tons) Figure 56. Global Neuroprotective Products Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Neuroprotective Products Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Neuroprotective Products Revenue (2021-2032) & (US$ Million) Figure 59. North America Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Neuroprotective Products Revenue (2021-2032) & (US$ Million) Figure 61. Europe Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Neuroprotective Products Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Neuroprotective Products Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Neuroprotective Products Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Neuroprotective Products Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Cholinesterase inhibitors
  • NMDA receptor antagonists
  • Others
Applications
  • Alzheimer's disease
  • Multiple sclerosis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis
  • Merck KGaA
  • Pfizer Inc
  • GlaxoSmithKline plc.
  • Biogen
  • AstraZeneca
  • Sunovion Pharmaceuticals Inc
  • NeuroVive Pharmaceutical
  • Neuren Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Genervon Biopharmaceuticals
  • Ceregene
  • Bionure
  • Bioniz Theraputics.
  • BHR Pharma
  • Allon therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuroprotective Products Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuroprotective Products Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neuroprotective Products Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neuroprotective Products Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neuroprotective Products Market Dynamics
  1. 2.1 Neuroprotective Products Industry Trends
  2. 2.2 Neuroprotective Products Industry Drivers
  3. 2.3 Neuroprotective Products Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Products Industry Restraints
3 Neuroprotective Products Market by Manufacturers
  1. 3.1 Global Neuroprotective Products Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neuroprotective Products Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neuroprotective Products Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neuroprotective Products Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuroprotective Products Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neuroprotective Products Manufacturers, Product Type & Application
  7. 3.7 Global Neuroprotective Products Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuroprotective Products Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuroprotective Products Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuroprotective Products Tier 1, Tier 2, and Tier 3
4 Neuroprotective Products Market by Type
  1. 4.1 Neuroprotective Products Type Introduction
  2. 4.1.1 Cholinesterase inhibitors
  3. 4.1.2 NMDA receptor antagonists
  4. 4.1.3 Others
  5. 4.2 Global Neuroprotective Products Sales by Type
  6. 4.2.1 Global Neuroprotective Products Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroprotective Products Sales by Type (2021-2032)
  8. 4.2.3 Global Neuroprotective Products Sales Market Share by Type (2021-2032)
  9. 4.3 Global Neuroprotective Products Revenue by Type
  10. 4.3.1 Global Neuroprotective Products Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neuroprotective Products Revenue by Type (2021-2032)
  12. 4.3.3 Global Neuroprotective Products Revenue Market Share by Type (2021-2032)
5 Neuroprotective Products Market by Application
  1. 5.1 Neuroprotective Products Application Introduction
  2. 5.1.1 Alzheimer's disease
  3. 5.1.2 Multiple sclerosis
  4. 5.1.3 Others
  5. 5.2 Global Neuroprotective Products Sales by Application
  6. 5.2.1 Global Neuroprotective Products Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroprotective Products Sales by Application (2021-2032)
  8. 5.2.3 Global Neuroprotective Products Sales Market Share by Application (2021-2032)
  9. 5.3 Global Neuroprotective Products Revenue by Application
  10. 5.3.1 Global Neuroprotective Products Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroprotective Products Revenue by Application (2021-2032)
  12. 5.3.3 Global Neuroprotective Products Revenue Market Share by Application (2021-2032)
6 Global Neuroprotective Products Sales by Region
  1. 6.1 Global Neuroprotective Products Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroprotective Products Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroprotective Products Sales by Region (2021-2026)
  4. 6.2.2 Global Neuroprotective Products Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neuroprotective Products Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neuroprotective Products Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neuroprotective Products Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neuroprotective Products Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neuroprotective Products Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neuroprotective Products Revenue by Region
  1. 7.1 Global Neuroprotective Products Revenue by Region
  2. 7.1.1 Global Neuroprotective Products Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neuroprotective Products Revenue by Region (2021-2026)
  4. 7.1.3 Global Neuroprotective Products Revenue by Region (2027-2032)
  5. 7.1.4 Global Neuroprotective Products Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neuroprotective Products Revenue (2021-2032)
  8. 7.2.2 North America Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neuroprotective Products Revenue (2021-2032)
  11. 7.3.2 Europe Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neuroprotective Products Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neuroprotective Products Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neuroprotective Products Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Products Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Neuroprotective Products Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck KGaA
  14. 8.3.1 Merck KGaA Company Information
  15. 8.3.2 Merck KGaA Business Overview
  16. 8.3.3 Merck KGaA Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck KGaA Neuroprotective Products Product Portfolio
  18. 8.3.5 Merck KGaA Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc Neuroprotective Products Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 GlaxoSmithKline plc.
  26. 8.5.1 GlaxoSmithKline plc. Company Information
  27. 8.5.2 GlaxoSmithKline plc. Business Overview
  28. 8.5.3 GlaxoSmithKline plc. Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline plc. Neuroprotective Products Product Portfolio
  30. 8.5.5 GlaxoSmithKline plc. Recent Developments
  31. 8.6 Biogen
  32. 8.6.1 Biogen Company Information
  33. 8.6.2 Biogen Business Overview
  34. 8.6.3 Biogen Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biogen Neuroprotective Products Product Portfolio
  36. 8.6.5 Biogen Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Neuroprotective Products Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Sunovion Pharmaceuticals Inc
  44. 8.8.1 Sunovion Pharmaceuticals Inc Company Information
  45. 8.8.2 Sunovion Pharmaceuticals Inc Business Overview
  46. 8.8.3 Sunovion Pharmaceuticals Inc Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sunovion Pharmaceuticals Inc Neuroprotective Products Product Portfolio
  48. 8.8.5 Sunovion Pharmaceuticals Inc Recent Developments
  49. 8.9 NeuroVive Pharmaceutical
  50. 8.9.1 NeuroVive Pharmaceutical Company Information
  51. 8.9.2 NeuroVive Pharmaceutical Business Overview
  52. 8.9.3 NeuroVive Pharmaceutical Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NeuroVive Pharmaceutical Neuroprotective Products Product Portfolio
  54. 8.9.5 NeuroVive Pharmaceutical Recent Developments
  55. 8.10 Neuren Pharmaceuticals
  56. 8.10.1 Neuren Pharmaceuticals Company Information
  57. 8.10.2 Neuren Pharmaceuticals Business Overview
  58. 8.10.3 Neuren Pharmaceuticals Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Neuren Pharmaceuticals Neuroprotective Products Product Portfolio
  60. 8.10.5 Neuren Pharmaceuticals Recent Developments
  61. 8.11 Hikma Pharmaceuticals PLC
  62. 8.11.1 Hikma Pharmaceuticals PLC Company Information
  63. 8.11.2 Hikma Pharmaceuticals PLC Business Overview
  64. 8.11.3 Hikma Pharmaceuticals PLC Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hikma Pharmaceuticals PLC Neuroprotective Products Product Portfolio
  66. 8.11.5 Hikma Pharmaceuticals PLC Recent Developments
  67. 8.12 Genervon Biopharmaceuticals
  68. 8.12.1 Genervon Biopharmaceuticals Company Information
  69. 8.12.2 Genervon Biopharmaceuticals Business Overview
  70. 8.12.3 Genervon Biopharmaceuticals Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Genervon Biopharmaceuticals Neuroprotective Products Product Portfolio
  72. 8.12.5 Genervon Biopharmaceuticals Recent Developments
  73. 8.13 Ceregene
  74. 8.13.1 Ceregene Company Information
  75. 8.13.2 Ceregene Business Overview
  76. 8.13.3 Ceregene Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ceregene Neuroprotective Products Product Portfolio
  78. 8.13.5 Ceregene Recent Developments
  79. 8.14 Bionure
  80. 8.14.1 Bionure Company Information
  81. 8.14.2 Bionure Business Overview
  82. 8.14.3 Bionure Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bionure Neuroprotective Products Product Portfolio
  84. 8.14.5 Bionure Recent Developments
  85. 8.15 Bioniz Theraputics.
  86. 8.15.1 Bioniz Theraputics. Company Information
  87. 8.15.2 Bioniz Theraputics. Business Overview
  88. 8.15.3 Bioniz Theraputics. Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bioniz Theraputics. Neuroprotective Products Product Portfolio
  90. 8.15.5 Bioniz Theraputics. Recent Developments
  91. 8.16 BHR Pharma
  92. 8.16.1 BHR Pharma Company Information
  93. 8.16.2 BHR Pharma Business Overview
  94. 8.16.3 BHR Pharma Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BHR Pharma Neuroprotective Products Product Portfolio
  96. 8.16.5 BHR Pharma Recent Developments
  97. 8.17 Allon therapeutics
  98. 8.17.1 Allon therapeutics Company Information
  99. 8.17.2 Allon therapeutics Business Overview
  100. 8.17.3 Allon therapeutics Neuroprotective Products Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Allon therapeutics Neuroprotective Products Product Portfolio
  102. 8.17.5 Allon therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroprotective Products Value Chain Analysis
  2. 9.1.1 Neuroprotective Products Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroprotective Products Production Mode & Process
  6. 9.2 Neuroprotective Products Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroprotective Products Distributors
  9. 9.2.3 Neuroprotective Products Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst